Total Funding
54
50
Total FundingPost-IPO Equity raised
Growth Score
-13 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
102913
Shield Therapeutics is a pharmaceutical company developing and commercializing late-stage, mineral-derived pharmaceuticals.
Jose A. Menoyo: Chief Medical OfficerPast Role: Alexion Pharmaceuticals, Head of US Medical Affairs- Christian Schweiger: Founder and Board MemberPast Role: Shield Therapeutics, Co-Founder & CMO
About the Company
Shield Therapeutics is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. During 2011 Shield will be commencing global pivotal Phase III studies of its lead asset, ST10-021, for the treatment of iron
deficiency anaemia associated with inflammatory bowel disease and subsequently chronic kidney disease. The Company is headquartered in Wollerau, Switzerland.
